Peter K. S. Siegl, Ph.D.
Dr. Siegl has practical knowledge of and extensive experience in drug discovery, drug development and regulatory strategy based upon his 26+ year tenure at Merck Research Laboratories (MRL) as well as active participation in professional scientific societies and professional organizations. He received his training as a pharmacologist at Philadelphia College of Pharmacy and Science and the University of British Columbia (Faculty of Pharmaceutical Sciences).
Dr. Siegl has actively contributed to the external scientific and regulatory drug development landscape. He has more than 100 scientific publications in peer review journals and several book chapters. He is one of the founders and was first president of the Safety Pharmacology Society (2001). In 2008, Dr. Siegl was recognized by the Safety Pharmacology Society via the Distinguished Service Award. He chaired the ILSI/Health and Environmental Science Institute Cardiovascular Safety Subcommittee (2002-2006) and was Deputy Topic Leader representing PhRMA on the International Conference on Harmonization: Topic ICH S7B, "Guideline on Safety Pharmacology Studies for Assessing the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals". He was a Safety Pharmacology Technical Group Co-Leader in the PhRMA DruSafe (Drug Safety) Committee (2000-2007).
Dr. Siegl is currently an independent consultant focusing on strategy and risk assessments for new drug discovery and development programs. He provides scientific and regulatory evaluation and recommendations of projects for Pharma, Biotech and CRO companies with clients in all three regions (US, EU and Asia).